Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin B6 (pyridoxal 5'-phosphate) has some scientific basis for its use as an adjunct in the management of rheumatoid arthritis (RA), although the evidence is not robust. Several studies have observed that patients with RA often have lower plasma levels of vitamin B6, and the degree of deficiency correlates with markers of inflammation, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). This deficiency is thought to be a consequence of the chronic inflammatory process rather than a cause of the disease.

Some randomized controlled trials have explored the effects of vitamin B6 supplementation in RA. For example, a 2005 double-blind trial (Huang et al.) found that supplementation with 50 mg/day of pyridoxine for 12 weeks corrected B6 deficiency and reduced certain markers of inflammation, but it did not lead to significant improvements in clinical symptoms or disease activity scores in RA patients. The evidence suggests that while B6 supplementation may normalize biochemical abnormalities, it does not directly modify the course of RA or provide symptomatic relief.

Thus, the use of vitamin B6 in RA is scientifically justified only to correct a documented deficiency, not as a stand-alone treatment for RA itself. Clinical guidelines do not recommend B6 supplementation as a primary therapy for RA. Overall, the evidence supporting its use is modest (rated 2), with supplementation best reserved for patients with demonstrated deficiency.

More about Vitamin B6 (pridoxal 5-phosphate)
More about Rheumatoid Arthritis

Other ingredients used for Rheumatoid Arthritis

Other health conditions supported by Vitamin B6 (pridoxal 5-phosphate)

Products containing Vitamin B6 (pridoxal 5-phosphate)